Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Quadrivalent HPV Vaccine in 18-45 Year Old Chinese Women
CTR20222643Phase 3Terminated
- Sponsor
- Shanghai Bowei Biopharmaceutical
- Start
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of CERVAVAC in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), Cervical Cancer (CC), anogenital warts, sponsored by Shanghai Bowei Biopharmaceutical. Started Oct 2022; status: terminated.
02
Drugs
CERVAVAC
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)anogenital warts
Beyond the preview
Go deeper on CTR20222643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222643.